Breakfast Technical Briefing on Generic Drugs Stocks -- Innocoll, Rigel Pharma, Tetraphase Pharma, and Catalent

NEW YORK, June 5, 2017 /PRNewswire/ --

Pre-market, DailyStockTracker.com monitors the performances of select Generic Drugs stocks, namely: Innocoll Holdings PLC (NASDAQ: INNL), Rigel Pharmaceuticals Inc. (NASDAQ: RIGL), Tetraphase Pharmaceuticals Inc. (NASDAQ: TTPH), and Catalent Inc. (NYSE: CTLT). According to an IBISWorld report, the Generic Pharmaceutical Manufacturing industry is expanding rapidly. An aging population with more chronic illnesses is driving demand for industry products, while regulatory provisions of the Patient Protection and Affordable Care Act expand consumer access to prescription insurance, and provide increased opportunities for product development. Daily Stock Tracker published free research reports on these stocks today at:

http://dailystocktracker.com/register/

Innocoll  

Athlone, Ireland headquartered Innocoll Holdings PLC's stock saw a slight drop of 0.46%, finishing last Friday's trading session at $2.16. A total volume of 39,515 shares was traded. The Company's shares have gained 4.35% in the last month, 200.00% over the previous three months, and 213.04% since the start of this year. The stock is trading above its 50-day moving average by 12.31%. Additionally, shares of Innocoll, which manufactures and sells collagen-based pharmaceutical products and devices in Europe, Middle-East, Asia, and the US, have a Relative Strength Index (RSI) of 58.60. See our free and comprehensive research report on INNL at:

http://dailystocktracker.com/registration/?symbol=INNL

Rigel Pharma  

Shares in South San Francisco, California-based Rigel Pharmaceuticals Inc. ended at $2.42, up 2.11% from the last trading session. The stock recorded a trading volume of 547,554 shares. The Company's shares have advanced 1.68% since the start of this year. The stock is trading 14.13% below its 200-day moving average. Moreover, shares of Rigel Pharma, which engages in the discovery and development of drugs in the therapeutic areas of immunology, oncology, and immuno-oncology, have an RSI of 36.48.

On June 01^st, 2017, Rigel Pharma announced that Ryan Maynard, the Company's CFO, is scheduled to present a company overview at the Jefferies 2017 Global Healthcare Conference on Wednesday, June 07^th, 2017, at 11:30 a.m. EDT. The live webcast of the presentation and its subsequent archived recording can be accessed on the Company's website. RIGL free research report is just a click away at:

http://dailystocktracker.com/registration/?symbol=RIGL

Tetraphase Pharma  

On Friday, shares in Watertown, Massachusetts headquartered Tetraphase Pharmaceuticals Inc. recorded a trading volume of 720,972 shares, which was above their three months average volume of 615,800 shares. The stock jumped 6.55%, closing the day at $7.65. The Company's shares have gained 20.66% over the previous three months and 89.83% on an YTD basis. The stock is trading 45.23% above its 200-day moving average. Additionally, shares of Tetraphase Pharma, which develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections, have an RSI of 50.87.

On May 30^th, 2017, Tetraphase Pharma announced that its management will give a corporate presentation at the Jefferies 2017 Global Healthcare Conference on June 07^th, 2017, at 08:00 a.m. ET at the Grand Hyatt Hotel in New York City. A live, audio webcast of the presentation will be available on the Company's website. Sign up for your complimentary report on TTPH at:

http://dailystocktracker.com/registration/?symbol=TTPH

Catalent  

At the close of trading on Friday, shares in Somerset, New Jersey headquartered Catalent Inc. recorded a trading volume of 733,586 shares, which was higher than their three months average volume of 691,010 shares. The stock finished the session 2.03% higher at $37.12. The Company's shares have gained 28.00% in the past month, 28.31% in the previous three months, and 37.69% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 21.75% and 36.80%, respectively. Furthermore, shares of Catalent, which provides advanced delivery technologies and development solutions for drugs, biologics, and consumer health products worldwide, have an RSI of 79.79.

On May 25^th, 2017, Catalent announced that Matthew Walsh, Executive Vice President and CFO, will present at the Jefferies 2017 Healthcare Conference on June 08^th, 2017, at 11:00 a.m. EDT in New York, NY. A live webcast of the presentation will be accessible on the Company's website. Register for free on DailyStockTracker.com and download the latest research report on CTLT at:

http://dailystocktracker.com/registration/?symbol=CTLT

--

Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@dailystocktracker.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY 

DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

http://dailystocktracker.com/disclaimer/

CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: contact@dailystocktracker.com
Phone number: (207)-331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA